Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma.
Egea-Rodriguez S, Váraljai R, Nordmann TM, Lubis R, Philip M, Rambow F, Roesch A, Flaig M, Horn S, Stoll R, Zhao F, Paschen A, Klebl B, Hickson ID, Schadendorf D, Mann M, Helfrich I. Egea-Rodriguez S, et al. Among authors: roesch a. Clin Transl Med. 2025 Jan;15(1):e70094. doi: 10.1002/ctm2.70094. Clin Transl Med. 2025. PMID: 39812592 Free PMC article.
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.
Albrecht LJ, Höwner A, Griewank K, Lueong SS, von Neuhoff N, Horn PA, Sucker A, Paschen A, Livingstone E, Ugurel S, Zimmer L, Horn S, Siveke JT, Schadendorf D, Váraljai R, Roesch A. Albrecht LJ, et al. Among authors: roesch a. Clin Transl Med. 2022 Nov;12(11):e1090. doi: 10.1002/ctm2.1090. Clin Transl Med. 2022. PMID: 36320118 Free PMC article.
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.
Stupia S, Heeke C, Brüggemann A, Zaremba A, Thier B, Kretz J, Sucker A, Philip M, Zelinskyy G, Ferrone S, Roesch A, Horn S, Hadaschik E, Schadendorf D, Trilling M, Dittmer U, Griewank K, Zhao F, Paschen A. Stupia S, et al. Among authors: roesch a. Clin Cancer Res. 2023 Aug 1;29(15):2894-2907. doi: 10.1158/1078-0432.CCR-23-0099. Clin Cancer Res. 2023. PMID: 37199727
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: roesch a. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
Early versus late response to PD-1-based immunotherapy in metastatic melanoma.
Lodde GC, Zhao F, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Jansen P, Kowall B, Galetzka W, Hörst F, Kleesiek J, Hellwig B, Rahnenführer J, Rajcsanyi L, Peters T, Hinney A, Placke JM, Sucker A, Paschen A, Becker JC, Livingstone E, Zimmer L, Tasdogan A, Roesch A, Hadaschik E, Schadendorf D, Griewank K, Ugurel S. Lodde GC, et al. Among authors: roesch a. Eur J Cancer. 2024 Oct;210:114295. doi: 10.1016/j.ejca.2024.114295. Epub 2024 Aug 23. Eur J Cancer. 2024. PMID: 39213786 Free article.
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma.
Placke JM, Bottek J, Váraljai R, Shannan B, Scharfenberg S, Krisp C, Spangenberg P, Soun C, Siemes D, Borgards L, Hoffmann F, Zhao F, Paschen A, Schlueter H, von Eggeling F, Helfrich I, Rambow F, Ugurel S, Tasdogan A, Schadendorf D, Engel DR, Roesch A. Placke JM, et al. Among authors: roesch a. Br J Dermatol. 2024 Dec 31:ljae433. doi: 10.1093/bjd/ljae433. Online ahead of print. Br J Dermatol. 2024. PMID: 39739311
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.
Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A. Zhao F, et al. Among authors: roesch a. Cancer Res. 2016 Aug 1;76(15):4347-58. doi: 10.1158/0008-5472.CAN-16-0008. Epub 2016 Jun 3. Cancer Res. 2016. PMID: 27261508
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Schadendorf D, et al. Among authors: roesch a. Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Lancet. 2018. PMID: 30238891 Review.
The predictive and prognostic significance of cell-free DNA concentration in melanoma.
Váraljai R, Elouali S, Lueong SS, Wistuba-Hamprecht K, Seremet T, Siveke JT, Becker JC, Sucker A, Paschen A, Horn PA, Neyns B, Weide B, Schadendorf D, Roesch A. Váraljai R, et al. Among authors: roesch a. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):387-395. doi: 10.1111/jdv.16766. Epub 2020 Jul 28. J Eur Acad Dermatol Venereol. 2021. PMID: 32569440
153 results